Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on KYOWA HAKKO KIRIN CO LTD
01/19 Patent Issued for Orally Disintegrating Tablet (USPTO 9861577)
01/09 KYOWA KIRIN : Creating opportunities from challenges
01/08 KYOWA HAKKO KIRIN : Notice Concerning Completion of Consolidated Subsidiary Shar..
01/04 KYOWA HAKKO KIRIN : Findings from Kyowa Hakko Kirin Co Reveals New Findings on D..
2017 KYOWA HAKKO KIRIN : Announces Changes in the Representative Directors
2017 BIOCENTURY - MANAGEMENT TRACKS : Vivus, Peregrine
2017 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for final dividend
2017 KYOWA HAKKO KIRIN : EMA committee recommends marketing approval for Burosumab to..
2017 Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
2017 Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
2017 KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
2017 KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
2017 KYOWA HAKKO KIRIN : Poteligeo meets in Phase III for CTCL
2017 REATA PHARMACEUTICALS, INC. (NASDAQ : RETA) Files An 8-K Entry into a Material D..
2017 KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
2017 Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
2017 Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
2017 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data fr..
2017 KYOWA HAKKO KIRIN : Submits the Partial Change Approval Application of Mogamuliz..
2017 KYOWA HAKKO KIRIN : Reports Outline Antisense Oligonucleotides Study Results fro..
2017 Ardelyx, Kyowa Hakko Kirin ink licensing pact for tenapanor for cardiorenal d..
2017 KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
2017 KYOWA HAKKO KIRIN : mogamulizumab gets Priority Review for CTCL
2017 KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
2017 KYOWA HAKKO KIRIN : Ardelyx and Kyowa Hakko Kirin Announce License Agreement for..
2017 KYOWA HAKKO KIRIN : "Protein Production Method" in Patent Application Approval P..
2017 KYOWA HAKKO KIRIN : Research Data from Kyowa Hakko Kirin Co Update Understanding..
2017 KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
2017 KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
2017 Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
2017 KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
2017 KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
2017 KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings
2017 Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
2017 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently ..
2017 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
2017 KYOWA HAKKO KIRIN : Concerning an Announcement by Kirin Holdings Company, Limite..
2017 KYOWA HAKKO KIRIN : Announces Initiation of the Phase III Clinical Study of KHK7..
2017 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
2017 KYOWA HAKKO KIRIN : Announces Marketing Authorisation Application for Mogamulizu..
2017 KYOWA HAKKO KIRIN : Matters Concerning Voluntary Adoption ofInternational Financ..
2017 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline for Parkinson's ..
2017 KYOWA HAKKO KIRIN : Announces the Intent to File Istradefylline (KW-6002) for Pa..
2017 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
2017 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
2017 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review ..
2017 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and..
2017 Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197
2017 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for t..
2017 KYOWA HAKKO KIRIN : Announces Discontinuation for Developing ARQ 197 (Tivantinib..
2017 SYNDAX PHARMACEUTICALS, INC. (NASDAQ : SNDX) Files An 8-K Other Events
2017 Kyowa Hakko Kirin Co., Ltd. - Notice Concerning Share Transfer Associated wit..
2017 KYOWA HAKKO KIRIN : Notice Concerning Share Transfer Associated with Change in a..
2017 Aveo oncology and eusa pharma announce tinivo combination study opt in
2017 KYOWA HAKKO KIRIN : Researchers Submit Patent Application, "Therapeutic Method a..
2017 Kyowa Hakko Kirin Co., Ltd. - Ultragenyx and Kyowa Hakko Kirin Announce Addit..
2017 KYOWA HAKKO KIRIN : Acquired Approval for Additional formulation of ACOALAN® in ..
2017 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosum..
2017 Kyowa Hakko Kirin Co., Ltd. - Announcement of submission of supplemental new ..
2017 KYOWA HAKKO KIRIN CO., LTD. : US Food and Drug Administration Grants Breakthroug..
2017 ANNOUNCEMENT OF SUBMISSION OF SUPPLE : Hft-290)(123kb)
2017 KYOWA HAKKO KIRIN CO. LTD. : - US Food and Drug Administration Grants Breakthrou..
2017 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Burosumab Data Presen..
2017 Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumabs Biologics ..
2017 KYOWA HAKKO KIRIN : US Food and Drug Administration Grants Breakthrough Therapy ..
2017 KYOWA HAKKO KIRIN CO., LTD. :  US Food and Drug Administration Grants Breakthrou..
2017 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Hakko Kirin Announce Submission of Buro..
2017 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Burosumab Data Presen..
2017 KYOWA HAKKO KIRIN : Patent Issued for Protein Production Method (USPTO 9725750)
2017 KYOWA HAKKO KIRIN : Kirin Chooses Verify Brand to Meet Compliance Mandates and G..
2017 KYOWA HAKKO KIRIN : and Kyowa Kirin International Announce Regulatory Updates fo..
2017 KYOWA HAKKO KIRIN CO LTD : ex-dividend day for interim dividend
2017 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris
2017 PARTNERSHIP AGREEMENT FOR A GEL FORM : Treatment for Psoriasis Vulgaris(130KB)
2017 KYOWA HAKKO KIRIN : Pharmaceutical firm boss applauds expansion work
1  2  3  4Next
Financials ( JPY)
Sales 2017 348 B
EBIT 2017 -
Net income 2017 22 498 M
Finance 2017 23 142 M
Yield 2017 1,16%
P/E ratio 2017 49,79
P/E ratio 2018 45,25
EV / Sales 2017 3,51x
EV / Sales 2018 3,49x
Capitalization 1 245 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 387  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Masashi Miyamoto Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD-2.84%11 243
ABBVIE7.91%166 806
MERCK KGAA0.41%14 160
JAZZ PHARMACEUTICALS PLC10.84%8 915
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD16.69%6 876
CONVATEC GROUP-7.30%5 070